Headlands Technologies LLC Purchases New Stake in Insulet Co. (NASDAQ:PODD)

Headlands Technologies LLC acquired a new position in Insulet Co. (NASDAQ:PODD) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 395 shares of the medical instruments supplier’s stock, valued at approximately $86,000.

Other hedge funds also recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust grew its position in Insulet by 251.0% in the third quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 123 shares during the period. Allworth Financial LP grew its position in Insulet by 104.5% in the third quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 92 shares during the period. Wolff Wiese Magana LLC boosted its position in shares of Insulet by 2,680.0% during the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 134 shares during the period. BluePath Capital Management LLC purchased a new position in shares of Insulet during the third quarter worth $31,000. Finally, Lindbrook Capital LLC boosted its position in shares of Insulet by 64.1% during the fourth quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock worth $42,000 after buying an additional 75 shares during the period.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. JPMorgan Chase & Co. raised their price target on Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Stifel Nicolaus raised their price target on Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research report on Monday, February 5th. Barclays lowered their price target on Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a research report on Monday, February 26th. Finally, Piper Sandler lowered their price target on Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a research report on Friday, February 23rd. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $243.21.

Insulet Price Performance

Shares of PODD opened at $171.94 on Wednesday. Insulet Co. has a twelve month low of $125.82 and a twelve month high of $335.91. The stock’s 50 day moving average is $171.09 and its two-hundred day moving average is $180.25. The firm has a market capitalization of $12.04 billion, a PE ratio of 59.09, a P/E/G ratio of 3.07 and a beta of 0.98. The company has a current ratio of 3.51, a quick ratio of 2.62 and a debt-to-equity ratio of 1.86.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.73. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The company had revenue of $509.80 million for the quarter, compared to analyst estimates of $461.26 million. During the same quarter in the previous year, the company earned $0.55 EPS. The firm’s revenue for the quarter was up 37.9% compared to the same quarter last year. Research analysts anticipate that Insulet Co. will post 3.08 earnings per share for the current year.

Insider Transactions at Insulet

In other news, Director Shacey Petrovic sold 11,609 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the sale, the director now owns 2,567 shares of the company’s stock, valued at approximately $418,215.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.47% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.